$5.23
6.44% yesterday
Nasdaq, Oct 03, 10:00 pm CET
ISIN
US74754R1032
Symbol
QLGN

Qualigen Therapeutics Inc Stock price

$5.23
+3.49 200.57% 1M
+1.92 58.01% 6M
+1.02 24.23% YTD
-2.77 34.63% 1Y
-129.77 96.13% 3Y
-2,494.77 99.79% 5Y
-306,244.77 100.00% 10Y
-619,994.77 100.00% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
-0.36 6.44%
ISIN
US74754R1032
Symbol
QLGN
Industry

Key metrics

Basic
Market capitalization
$8.9m
Enterprise Value
$12.2m
Net debt
$3.3m
Cash
$330.0k
Shares outstanding
1.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
57.2%
Return on Equity
-
ROCE
372.4%
ROIC
-338.0%
Debt/Equity
-2.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-6.2m | $-11.6m
Net Income
$-7.0m | $-1.2m
Free Cash Flow
$-6.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
24.7% | -
Net Income
28.3% | -
Free Cash Flow
3.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.2
FCF per Share
$-4.1
Short interest
2.3%
Employees
4
Rev per Employee
-
Show more

Is Qualigen Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Qualigen Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Qualigen Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Qualigen Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Qualigen Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.05 6.05
39% 39%
-
- Research and Development Expense 0.17 0.17
96% 96%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -6.18 -6.18
25% 25%
-
Net Profit -7.01 -7.01
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Qualigen Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Qualigen Therapeutics Inc Stock News

Neutral
GlobeNewsWire
4 days ago
New York, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of $41 million strategic investment in its client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen Therapertics”), a clinical-stage therapeutics company focused on de...
Neutral
GlobeNewsWire
4 days ago
Carlsbad, CA, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or “the Company”) today announced the successful closing of a $41 million private investment in public equity (PIPE) financing led by Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“FF”), along with its Founder and Global Co-CEO YT Jia, President Jerry Wang, SIGN Foundation – a bloc...
Neutral
GlobeNewsWire
15 days ago
LOS ANGELES and CARLSBAD, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility ecosystem company, and Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("QLGN"), jointly announced that they have entered into a securities purchase agreement (the “Agreement”) for a p...
More Qualigen Therapeutics Inc News

Company Profile

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company is headquartered in Los Angeles, CA.

Head office United States
CEO Kevin Richardson
Employees 4
Founded 2004
Website qlgntx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today